Combined therapy for multi-drug-resistant acinetobacter baumannii infection – is there evidence outside the laboratory?

Journal of Medical Microbiology

Volumn 64, Issue 9, 2015, Pages 951-959

  Tuon, Felipe F ^a,b,c   Rocha, Jaime L ^a,d   Merlini, Alexandre B ^e  

^a PONTIFÍCIA UNIVERSIDADE CATÓLICA DE CAMPINAS   (Brazil)

^b HOSPITAL UNIVERSITÁRIO EVANGÉLICO DE CURITIBA   (Brazil)

^c FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^d Division of Microbiology   (Brazil)

^e HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CARBAPENEM; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; DEVELOPED COUNTRY; DRUG POTENTIATION; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; MONOTHERAPY; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; ACINETOBACTER INFECTIONS; DRUG EFFECTS; MICROBIOLOGY;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS;

EID: 84941564519     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.000144     Document Type: Article

References (85)

1. Alp, E., Esel, D., Yildiz, O., Voss, A., Melchers, W. & Doganay, M. (2006). Genotypic analysis of Acinetobacter bloodstream infection isolates in a Turkish university hospital. Scand J Infect Dis 38, 335–340.
2. Arroyo, L.A., Mateos, I., González, V. & Aznar, J. (2009). In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group. Antimicrob Agents Chemother 53, 1295–1296.
3. Bassetti, M., Repetto, E., Righi, E., Boni, S., Diverio, M., Molinari, M.P., Mussap, M., Artioli, S., Ansaldi, F., Durando, P., Orengo, G., Bobbio Pallavicini, F. & Viscoli, C. (2003). Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 61, 417–20.
4. Baumgart, A. M., Molinari, M. A. & Silveira, A. C. (2010). Prevalence of carbapenem resistant Pseudomonas aeruginosa and Acinetobacter baumannii in high complexity hospital. Braz J Infect Dis 14, 433–436.
5. Bernabeu-Wittel, M., Pichardo, C., García-Curiel, A., Pachón-Ibáñez, M. E., Ibáñez-Martínez, J., Jiménez-Mejías, M. E. & Pachón, J. (2005). Pharmacokinetic/pharmacodynamic assessment of the in-vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant Acinetobacter baumannii pneumonia. Clin Microbiol Infect 11, 319–325.
6. Cereda, R. F., Azevedo, H. D., Girardello, R., Xavier, D. E., Gales, A. C. & INVITA-A-CEFTO Brazilian Study Group (2011). Antimicrobial activity of ceftobiprole against Gram-negative and Gram-positive pathogens: results from INVITA-A-CEFTO Brazilian study. Braz J Infect Dis 15, 339–348.
7. Chang, S. C., Chen, Y. C., Luh, K. T. & Hsieh, W. C. (1995). In vitro activities of antimicrobial agents, alone and in combination, against Acinetobacter baumannii isolated from blood. Diagn Microbiol Infect Dis 23, 105–110.
8. Choi, M. J., Park, Y. K., Peck, K. R. & Ko, K. S. (2014). Mutant prevention concentrations of colistin used in combination with other antimicrobial agents against Acinetobacter baumannii, Klebsiella pneumoniae and Pseudomonas aeruginosa clinical isolates. Int J Antimicrob Agents 44, 475–476.
9. Christie, C., Mazon, D., Hierholzer, W., Jr & Patterson, J. E. (1995). Molecular heterogeneity of Acinetobacter baumanii isolates during seasonal increase in prevalence. Infect Control Hosp Epidemiol 16, 590–594.
10. Chu, H., Zhao, L., Wang, M., Liu, Y., Gui, T. & Zhang, J. (2013). Sulbactam-based therapy for Acinetobacter baumannii infection: a systematic review and meta-analysis. Braz J Infect Dis 17, 389–394.
11. Cieslinski, J. M., Arend, L., Tuon, F. F., Silva, E. P., Ekermann, R. G., Dalla-Costa, L. M., Higgins, P. G., Seifert, H. & Pilonetto, M. (2013). Molecular epidemiology characterization of OXA-23 carbapenemaseproducing Acinetobacter baumannii isolated from 8 Brazilian hospitals using repetitive sequence-based PCR. Diagn Microbiol Infect Dis 77, 337–340.
12. Corrêa, L. L., Botelho, L. A., Barbosa, L. C., Mattos, C. S., Carballido, J. M., de Castro, C. L., Mondino, P. J., de Paula, G. R., de Mondino, S. S. & de Mendonça-Souza, C. R. (2012). Detection of blaOXA-23 in Acinetobacter spp. isolated from patients of a university hospital. Braz J Infect Dis 16, 521–526.
13. Cullmann, W., Opferkuch, W., Stieglitz, M. & Werkmeister, U. (1982). A comparison of the antibacterial activities of N-formimidoyl thienamycin (MK0787) with those of other recently developed betalactam derivatives. Antimicrob Agents Chemother 22, 302–307.
14. Curcio, D., Fernández, F., Cané, A., Barcelona, L. & Stamboulian, D. (2008). Indications of a new antibiotic in clinical practice: results of the tigecycline initial use registry. Braz J Infect Dis 12, 198–201.
15. Dalla-Costa, L. M., Coelho, J. M., Souza, H. A., Castro, M. E., Stier, C. J., Bragagnolo, K. L., Rea-Neto, A., Penteado-Filho, S. R., Livermore, D. M. & Woodford, N. (2003). Outbreak of carbapenemresistant Acinetobacter baumannii producing the OXA-23 enzyme in Curitiba, Brazil. J Clin Microbiol 41, 3403–3406.
16. Drago, L., De Vecchi, E., Nicola, L., Tocalli, L. & Gismondo, M. R. (2005). In vitro selection of resistance in Pseudomonas aeruginosa and Acinetobacter spp. by levofloxacin and ciprofloxacin alone and in combination with β-lactams and amikacin. J Antimicrob Chemother 56, 353–359.
17. Dync, G., Demiraslan, H., Elmali, F., Ahmed, S. S., Alp, E. & Doganay, M. (2015). Antimicrobial efficacy of doripenem and its combinations with sulbactam, amikacin, colistin, tigecycline in experimental sepsis of carbapenem-resistant Acinetobacter baumannii. New Microbiol 38, 67–73.
18. Gales, A. C., Azevedo, H. D., Cereda, R. F., Girardello, R., Xavier, D. E. & INVITA-A-DORI Brazilian Study Group (2011). Antimicrobial activity of doripenem against Gram-negative pathogens: results from INVITA-A-DORI Brazilian study. Braz J Infect Dis 15, 513–520.
19. Giamarellou, H., Sfikakis, P., Voutsinas, D., Galanakis, N. & Daikos, G. K. (1986). Evaluation of imipenem/cilastatin against nosocomial infections and multiresistant pathogens. J Antimicrob Chemother 18 (Suppl. E), 175–179.
20. Go, E. S., Urban, C., Burns, J., Kreiswirth, B., Eisner, W., Mariano, N., Mosinka-Snipas, K. & Rahal, J. J. (1994). Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet 344, 1329–1332.
21. Guarnacho-Montero, J., Ortiz-Leyba, C., Jiménez-Jiménez, F.J., Barrero-Almodóvar, A.E., García-Garmendia, J.L., Bernabeu-Wittell, M., Gallego-Lara, S.L. & Madrazo-Osuna, J. (2013). Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 36, 1111–8.
22. Guner, R., Hasanoglu, I., Keske, S., Kalem, A.K. & Tasyaran, M.A. (2011). Outcomes in patients infected with carbapenem-resistant Acinetobacter baumannii and treated with tigecycline alone or in combination therapy. Infection 39, 515–8.
23. Heyland, D. K., Dodek, P., Muscedere, J., Day, A., Cook, D. & Canadian Critical Care Trials Group (2008). Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilatorassociated pneumonia. Crit Care Med 36, 737–744.
24. Hogg, G. M., Barr, J. G. & Webb, C. H. (1998). In-vitro activity of the combination of colistin and rifampicin against multidrug-resistant strains of Acinetobacter baumannii. J Antimicrob Chemother 41, 494–495.
25. Hornsey, M. & Wareham, D. W. (2011). In vivo efficacy of glycopeptide-colistin combination therapies in a Galleria mellonella model of Acinetobacter baumannii infection. Antimicrob Agents Chemother 55, 3534–3537.
26. Hornsey, M., Longshaw, C., Phee, L. & Wareham, D. W. (2012). In vitro activity of telavancin in combination with colistin versus Gram-negative bacterial pathogens. Antimicrob Agents Chemother 56, 3080–3085.
27. Hornsey, M., Phee, L., Longshaw, C. & Wareham, D. W. (2013). In vivo efficacy of telavancin/colistin combination therapy in a Galleria mellonella model of Acinetobacter baumannii infection. Int J Antimicrob Agents 41, 285–287.
28. Joly-Guillou, M. L., Bergogne-Berezin, E. & Vieu, J. F. (1990). [Epidemiology of Acinetobacter and resistance to antibiotics at hospitals. A 5-year evaluation]. Presse Med 19, 357–361 (in French).
29. Joly-Guillou, M. L., Wolff, M., Farinotti, R., Bryskier, A. & Carbon, C. (2000). In vivo activity of levofloxacin alone or in combination with imipenem or amikacin in a mouse model of Acinetobacter baumannii pneumonia. J Antimicrob Chemother 46, 827–830.
30. Kiffer, C. R., Sampaio, J. L., Sinto, S., Oplustil, C. P., Koga, P. C., Arruda, A. C., Turner, P. J. & Mendes, C. (2005). In vitro synergy test of meropenem and sulbactam against clinical isolates of Acinetobacter baumannii. Diagn Microbiol Infect Dis 52, 317–322.
31. Kitzis, M. D., Goldstein, F. W., Labia, R. & Acar, J. F. (1983). [Activity of sulbactam and clavulanic acid, alone and combined, on Acinetobacter calcoaceticus]. Ann Microbiol (Paris) 134A, 163–168 (in French).
32. Kuo, L. C., Lai, C. C., Liao, C. H., Hsu, C. K., Chang, Y. L., Chang, C. Y. & Hsueh, P. R. (2007). Multidrug-resistant Acinetobacter baumannii bacteraemia: clinical features, antimicrobial therapy and outcome. Clin Microbiol Infect 13, 196–198.
33. Lee, Y. T., Tsao, S. M. & Hsueh, P. R. (2013). Clinical outcomes of tigecycline alone or in combination with other antimicrobial agents for the treatment of patients with healthcare-associated multidrugresistant Acinetobacter baumannii infections. Eur J Clin Microbiol Infect Dis 32, 1211–1220.
34. Levin, A. S., Barone, A. A., Penço, J., Santos, M. V., Marinho, I. S., Arruda, E. A., Manrique, E. I. & Costa, S. F. (1999). Intravenous colistin as therapy for nosocomial infections caused by multidrugresistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 28, 1008–1011.
35. Levin, A. S., Levy, C. E., Manrique, A. E., Medeiros, E. A. & Costa, S. F. (2003). Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam. Int J Antimicrob Agents 21, 58–62.
36. Lim, T. P., Tan, T. Y., Lee, W., Sasikala, S., Tan, T. T., Hsu, L. Y. & Kwa, A. L. (2011). In-vitro activity of polymyxin B, rifampicin, tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii in Singapore. PLoS One 6, e18485.
37. Lima, A. L., Oliveira, P. R., Paula, A. P., Dal-Paz, K., Almeida, J. N., Jr, Félix, C. S. & Rossi, F. (2011). Carbapenem stewardship: positive impact on hospital ecology. Braz J Infect Dis 15, 1–5.
38. Magiorakos, A. P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G., Harbarth, S., Hindler, J. F., Kahlmeter, G. & other authors (2012). Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18, 268–281.
39. Markou, N., Apostolakos, H., Koumoudiou, C., Athanasiou, M., Koutsoukou, A., Alamanos, I. & Gregorakos, L. (2003). Intravenous colistin in the treatment of sepsis from multiresistant Gramnegative bacilli in critically ill patients. Crit Care 7, R78–R83.
40. Martinez-Martinez, L., Rodriguez, G., Pascual, A., Suárez, A. I. & Perea, E. J. (1996). In-vitro activity of antimicrobial agent combinations against multiresistant Acinetobacter baumannii. J Antimicrob Chemother 38, 1107–1108.
41. Medell, M., Hart, M., Marrero, O., Espinosa, F., Montes de Oca, Z. & Valdés, R. (2012). Clinical and microbiological characterization of pneumonia in mechanically ventilated patients. Braz J Infect Dis 16, 442–447.
42. Metan, G., Alp, E., Aygen, B. & Sumerkan, B. (2007). Acinetobacter baumannii meningitis in post-neurosurgical patients: clinical outcome and impact of carbapenem resistance. J Antimicrob Chemother 60, 197–199.
43. Michalopoulos, A. S., Tsiodras, S., Rellos, K., Mentzelopoulos, S. & Falagas, M. E. (2005). Colistin treatment in patients with ICUacquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect 11, 115–121.
44. Motaouakkil, S., Charra, B., Hachimi, A. & Benslama, A. (2006a). [Nosocomial pneumonia caused by multiresistant Acinetobacter baumanii treated by colistin and rifampicin]. Ann Fr Anesth Reanim 25, 543–544 (in French).
45. Motaouakkil, S., Charra, B., Hachimi, A., Nejmi, H., Benslama, A., Elmdaghri, N., Belabbes, H. & Benbachir, M. (2006b). Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. J Infect 53, 274–278.
46. Mukhopadhyay, C., Krishna, S., Vandana, K. E., Shenoy, A. & Bairy, I. (2008). Ventilator-associated pneumonia with Col-S strains: a successful comeback of colistin! Braz J Infect Dis 12, 444–446.
47. Mutlu Yilmaz, E., Sunbul, M., Aksoy, A., Yilmaz, H., Guney, A. K. & Guvenc, T. (2012). Efficacy of tigecycline/colistin combination in a pneumonia model caused by extensively drug-resistant Acinetobacter baumannii. Int J Antimicrob Agents 40, 332–336.
48. Ni, W., Shao, X., Di, X., Cui, J., Wang, R. & Liu, Y. (2015). In vitro synergy of polymyxins with other antibiotics for Acinetobacter baumannii: a systematic review and meta-analysis. Int J Antimicrob Agents 45, 8–18.
49. Oliveira, M. S., Prado, G. V., Costa, S. F., Grinbaum, R. S. & Levin, A. S. (2008). Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother 61, 1369–1375.
50. Ouderkirk, J. P., Nord, J. A., Turett, G. S. & Kislak, J. W. (2003). Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant Gram-negative bacteria. Antimicrob Agents Chemother 47, 2659–2662.
51. Pantopoulou, A., Giamarellos-Bourboulis, E. J., Raftogannis, M., Tsaganos, T., Dontas, I., Koutoukas, P., Baziaka, F., Giamarellou, H. & Perrea, D. (2007). Colistin offers prolonged survival in experimental infection by multidrug-resistant Acinetobacter baumannii: the significance of co-administration of rifampicin. Int J Antimicrob Agents 29, 51–55.
52. Peleg, A. Y., Jara, S., Monga, D., Eliopoulos, G. M., Moellering, R. C., Jr & Mylonakis, E. (2009). Galleria mellonella as a model system to study Acinetobacter baumannii pathogenesis and therapeutics. Antimicrob Agents Chemother 53, 2605–2609.
53. Petrosillo, N., Chinello, P., Proietti, M. F., Cecchini, L., Masala, M., Franchi, C., Venditti, M., Esposito, S. & Nicastri, E. (2005). Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical outcome and adverse events. Clin Microbiol Infect 11, 682–683.
54. Pilonetto, M., Rosa, E. A., Brofman, P. R., Baggio, D., Calvário, F., Schelp, C., Nascimento, A. & Messias-Reason, I. (2004). Hospital gowns as a vehicle for bacterial dissemination in an intensive care unit. Braz J Infect Dis 8, 206–210.
55. Principe, L., D’Arezzo, S., Capone, A., Petrosillo, N. & Visca, P. (2009). In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii. Ann Clin Microbiol Antimicrob 8, 18.
56. Raka, L., Kalenć, S., Bosnjak, Z., Budimir, A., Katić, S., Sijak, D., Mulliqi-Osmani, G., Zoutman, D. & Jaka, A. (2009). Molecular epidemiology of Acinetobacter baumannii in central intensive care unit in Kosova Teaching Hospital. Braz J Infect Dis 13, 408–413.
57. Rodríguez-Hernández, M. J., Pachón, J., Pichardo, C., Cuberos, L., Ibáñez-Martínez, J., García-Curiel, A., Caballero, F. J., Moreno, I. & Jiménez-Mejías, M. E. (2000). Imipenem, doxycycline and amikacin in monotherapy and in combination in Acinetobacter baumannii experimental pneumonia. J Antimicrob Chemother 45, 493–501.
58. Romanelli, R. M., Jesus, L. A., Clemente, W. T., Lima, S. S., Rezende, E. M., Coutinho, R. L., Moreira, R. L., Neves, F. A. & Brás, N. J. (2009). Outbreak of resistant Acinetobacter baumannii – measures and proposal for prevention and control. Braz J Infect Dis 13, 341–347.
59. Rossi, F., García, P., Ronzon, B., Curcio, D. & Dowzicky, M. J. (2008). Rates of antimicrobial resistance in Latin America (2004-2007) and in vitro activity of the glycylcycline tigecycline and of other antibiotics. Braz J Infect Dis 12, 405–415.
60. Sader, H. S. (2000). Antimicrobial resistance in Brazil: comparison of results from two multicenter studies. Braz J Infect Dis 4, 91–99.
61. Sader, H. S. & Jones, R. N. (2005). Comprehensive in vitro evaluation of cefepime combined with aztreonam or ampicillin/sulbactam against multi-drug resistant Pseudomonas aeruginosa and Acinetobacter spp. Int J Antimicrob Agents 25, 380–384.
62. Sader, H. S., Sampaio, J. L., Zoccoli, C. & Jones, R. N. (1999). Results of the 1997 SENTRY antimicrobial surveillance program in three Brazilian medical centers. Braz J Infect Dis 3, 63–79.
63. Sader, H. S., Gales, A. C., Pfaller, M. A., Mendes, R. E., Zoccoli, C., Barth, A. & Jones, R. N. (2001). Pathogen frequency and resistance patterns in Brazilian hospitals: summary of results from three years of the SENTRY antimicrobial surveillance program. Braz J Infect Dis 5, 200–214.
64. Santimaleeworagun, W., Wongpoowarak, P., Chayakul, P., Pattharachayakul, S., Tansakul, P. & Garey, K. W. (2011). In vitro activity of colistin or sulbactam in combination with fosfomycin or imipenem against clinical isolates of carbapenem-resistant Acinetobacter baumannii producing OXA-23 carbapenemases. Southeast Asian J Trop Med Public Health 42, 890–900.
65. Savov, E., Chankova, D., Vatcheva, R. & Dinev, N. (2002). In vitro investigation of the susceptibility of Acinetobacter baumannii strains isolated from clinical specimens to ampicillin/sumbactam alone and in combination with amikacin. Int J Antimicrob Agents 20, 390–2.
66. Sengstock, D. M., Thyagarajan, R., Apalara, J., Mira, A., Chopra, T. & Kaye, K. S. (2010). Multidrug-resistant Acinetobacter baumannii: an emerging pathogen among older adults in community hospitals and nursing homes. Clin Infect Dis 50, 1611–1616.
67. Simsek, F. Gedik, H. Yildirmak, M.T. Iris, N.E. Turkmen, A. Ersoy, A. Ersoz, M. & Gucuyener, A. Colistin against colistin-only-susceptible Acinetobacter baumannii-related infections: monotherapy or combination therapy? Indian J Med Microbiol 30, 448–52.
68. Sobieszczyk, M. E., Furuya, E. Y., Hay, C. M., Pancholi, P., Della- Latta, P., Hammer, S. M. & Kubin, C. J. (2004). Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections. J Antimicrob Chemother 54, 566–569.
69. Song, J. Y., Cheong, H. J., Lee, J., Sung, A. K. & Kim, W. J. (2009). Efficacy of monotherapy and combined antibiotic therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model. Int J Antimicrob Agents 33, 33–39.
70. Tankovic, J., Legrand, P., De Gatines, G., Chemineau, V., Brun- Buisson, C. & Duval, J. (1994). Characterization of a hospital outbreak of imipenem-resistant Acinetobacter baumannii by phenotypic and genotypic typing methods. J Clin Microbiol 32, 2677–2681.
71. Tascini, C., Menichetti, F., Bozza, S., Del Favero, A. & Bistoni, F. (1998). Evaluation of the activities of two-drug combinations of rifampicin, polymyxin B and ampicillin/sulbactam against Acinetobacter baumannii. J Antimicrob Chemother 42, 270–271.
72. Teo, F., Jim, T.P., Hsu, L.Y., Tan, T.Y., Sasikala, S., Hon, P.Y., Kwa, A.L. & Apisarnthanarak, A. (2015). Extensively drug-resistant Acinetobacter baumannii in a Thai hospital: a molecular epidemiologic analysis and identification of bactericidal Polymyxin B-based combinations. Antimicrob Resist Infect Control 4:2.
73. Timurkaynak, F., Can, F., Azap, O. K., Demirbilek, M., Arslan, H. & Karaman, S. O. (2006). In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units. Int J Antimicrob Agents 27, 224–228.
74. Toledo, P. V., Arend, L. N., Pilonetto, M., Costa Oliveira, J. C., Luhm, K. R. & Working Group in Healthcare Associated Infections (WGHAI) (2012). Surveillance programme for multidrug-resistant bacteria in healthcare-associated infections: an urban perspective in South Brazil. J Hosp Infect 80, 351–353.
75. Tuon, F. F., Penteado-Filho, S. R., Amarante, D., Andrade, M. A. & Borba, L. A. (2010a). Mortality rate in patients with nosocomial Acinetobacter meningitis from a Brazilian hospital. Braz J Infect Dis 14, 437–440.
76. Tuon, F. F., Penteado-Filho, S. R., Amarante, D., Andrade, M. A. & Borba, L. A. (2010b). Mortality rate in patients with nosocomial Acinetobacter meningitis from a Brazilian hospital. Braz J Infect Dis 14, 437–440.
77. Tuon, F. F., Rymsza, A. M., Penteado-Filho, S. R., Pilonetto, M., Arend, L. N. & Levin, A. S. (2011). Should polymyxin be used empirically to treat infections in patients under high risk for carbapenem-resistant Acinetobacter? J Infect 62, 246–249.
78. Tuon, F. F., Rigatto, M. H., Lopes, C. K., Kamei, L. K., Rocha, J. L. & Zavascki, A. P. (2014). Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Int J Antimicrob Agents 43, 349–352.
79. Urban, C., Go, E., Mariano, N., Berger, B. J., Avraham, I., Rubin, D. & Rahal, J. J. (1993). Effect of sulbactam on infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus. J Infect Dis 167, 448–451.
80. Villegas, M. V., Briceno, D. F., Ruiz, S. J., Furtado, G. H. & Nicolau, D. P. (2011). Assessing the pharmacodynamic profile of intravenous antibiotics against prevalent Gram-negative organisms collected in Colombia. Braz J Infect Dis 15, 413–419.
81. Wareham, D. W. & Bean, D. C. (2006). In-vitro activity of polymyxin B in combination with imipenem, rifampicin and azithromycin versus multidrug resistant strains of Acinetobacter baumannii producing OXA-23 carbapenemases. Ann Clin Microbiol Antimicrob 5, 10.
82. Wolff, M., Joly-Guillou, M. L., Farinotti, R. & Carbon, C. (1999). In vivo efficacies of combinations of beta-lactams, beta-lactamase inhibitors, and rifampin against Acinetobacter baumannii in a mouse pneumonia model. Antimicrob Agents Chemother 43, 1406–1411.
83. Wood, C. A. & Reboli, A. C. (1993). Infections caused by imipenemresistant Acinetobacter calcoaceticus biotype anitratus. J Infect Dis 168, 1602–1603.
84. Yadav, R., Landersdorfer, C. B., Nation, R. L., Boyce, J. D. & Bulitta, J. B. (2015). Novel approach to optimize synergistic carbapenem-aminoglycoside combinations against carbapenemresistant Acineto-bacter baumannii. Antimicrob Agents Chemother 59, 2286–2298.
85. Zavascki, A. P., Goldani, L. Z., Cao, G., Superti, S. V., Lutz, L., Barth, A. L., Ramos, F., Boniatti, M. M., Nation, R. L. & Li, J. (2008). Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin Infect Dis 47, 1298–1304.